9995.HK Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 Jun 2024 @ 04:08):
Our systems believe the stock currently is undervalued by 0.06% compare to its pairs and should correct upwards.

Stats
Today's Volume	1.35M
Average Volume	1.51M
Market Cap	22.78B
EPS	HKD-0.650 ( Q1 \| 2024-03-31 )
Next earnings date	( HKD0 ) 2024-08-20
Last Dividend	HKD0 ( N/A )
Next Dividend	HKD0 ( N/A )
P/E	-8.14 (Sector) 14.27 (Industry) 6.31
ATR14	HKD0.0290 (0.12%)

0690.HK 0.00%

1061.HK -0.82%

1167.HK 3.31%

1177.HK -1.11%

1228.HK 0.00%

1477.HK 1.63%

1521.HK -2.44%

1530.HK 2.71%

1548.HK -1.42%

1672.HK -3.61%

1873.HK 0.00%

1875.HK -0.45%

1877.HK -0.51%

1952.HK -2.59%

2096.HK -0.69%

2126.HK -2.00%

2137.HK -0.98%

2142.HK 1.47%

2157.HK -3.80%

2162.HK -2.88%

2171.HK -2.04%

2179.HK -3.00%

2197.HK -1.45%

2256.HK -0.61%

2257.HK 0.00%

2616.HK 2.70%

2696.HK -0.65%

3759.HK -1.63%

6160.HK 1.17%

6600.HK 0.86%

6622.HK 0.71%

6628.HK 1.33%

6821.HK -0.10%

6826.HK 1.76%

6978.HK 23.00%

6996.HK 0.00%

6998.HK 0.00%

9688.HK -0.15%

9926.HK -2.33%

9939.HK -4.59%

9966.HK -0.41%

9969.HK 3.66%

9995.HK -4.67%

Correlation (AI algo v.1.1b): Undervalued: 0.06% HKD24.52 paired level. (The Algo Track The Changes Of The Most Correlated Stocks In Realtime And Give An Instant Update)

Volume Correlation

Long: -0.12 (neutral)

Short: 0.71 (moderate)

Signal:(46.118) Neutral

REMEGEN-B Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

REMEGEN-B Correlation - Currency/Commodity

-0.06
( neutral )

-0.15
( neutral )

0.00
( neutral )

-0.15
( neutral )

0.00
( neutral )

-0.08
( neutral )

REMEGEN-B Financials

Annual	2023
Revenue:	HKD1.08B
Gross Profit:	HKD822.99M (76.48 %)
EPS:	HKD-2.80

FY	2023
Revenue:	HKD1.08B
Gross Profit:	HKD822.99M (76.48 %)
EPS:	HKD-2.80

FY	2022
Revenue:	HKD767.78M
Gross Profit:	HKD497.84M (64.84 %)
EPS:	HKD-1.880

FY	2021
Revenue:	HKD1.42B
Gross Profit:	HKD1.36B (95.28 %)
EPS:	HKD0.680

Financial Reports:

No articles found.

REMEGEN-B Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

REMEGEN-B

RemeGen Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of biologics for the treatment of autoimmune, oncology, and ophthalmic diseases with unmet medical needs in Mainland China and the United States. The company offers Telitacicept (RC18) for use in the treatment of systemic lupus erythematosus an autoimmune disease and Disitamab Vedotin (RC48) for use in the treatment of various cancers. Its products in various stages of development include RC18, which is under phase III clinical trials for the treatment of neuromyelitis optica spectrum disorder and rheumatoid arthritis, and phase II clinical trials for the treatment of IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis; RC28, which has completed Phase 1 clinical trials for use in the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy; RC98, a PD-L1 monoclonal antibody for the treatment of solid tumors and is under Phase I clinical trial; RC88, which is in Phase 1 clinical trials for use in the treatment of mesothelioma, bile duct carcinoma, pancreatic cancer, ovarian carcinoma, lung adenocarcinoma, and other solid tumors, as well as lung and urothelial cancer; and RC108 that is in Phase 1 clinical trials to treat various solid tumors. In addition, the company's products under pre-clinical development include RC118, RC138, RC148, RC158, RC168, RC178, RC188, and RC198 to treat various solid tumors; and RC208, RC218, and RC228 to treat ophthalmic diseases. RemeGen Co., Ltd. was incorporated in 2008 and is headquartered in Yantai, the People's Republic of China.